These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1185 related articles for article (PubMed ID: 27893331)

  • 1. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI.
    Pituskin E; Haykowsky M; Mackey JR; Thompson RB; Ezekowitz J; Koshman S; Oudit G; Chow K; Pagano JJ; Paterson I
    BMC Cancer; 2011 Jul; 11():318. PubMed ID: 21794114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small benefits in trastuzumab-related cardiotoxicity.
    Das M
    Lancet Oncol; 2017 Jan; 18(1):e5. PubMed ID: 27956153
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
    Guglin M; Munster P; Fink A; Krischer J
    Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
    Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab.
    Huang F; Brezden-Masley C; Chan KKW; Barfett JJ; Kirpalani A; Deva DP; Jimenez-Juan L; Barthur A; Song L; Chacko B; Ng MY; Connelly K; Wong KCK; Yan AT
    Eur Radiol; 2022 Jun; 32(6):4234-4242. PubMed ID: 34993574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
    Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
    Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
    Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
    JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.
    Meattini I; Curigliano G; Terziani F; Becherini C; Airoldi M; Allegrini G; Amoroso D; Barni S; Bengala C; Guarneri V; Marchetti P; Martella F; Piovano P; Vannini A; Desideri I; Tarquini R; Galanti G; Barletta G; Livi L
    Med Oncol; 2017 May; 34(5):75. PubMed ID: 28364270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
    Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
    Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
    Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
    Guglin M; Krischer J; Tamura R; Fink A; Bello-Matricaria L; McCaskill-Stevens W; Munster PN
    J Am Coll Cardiol; 2019 Jun; 73(22):2859-2868. PubMed ID: 31171092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
    Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
    J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
    Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
    Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.